By A.J. Hostetler 

A blood-based score may help predict which patients with fatty liver disease are more likely to have serious problems, according to a new study led by a Virginia Commonwealth University hepatologist. 

The metabolic vulnerability index, or MVX, is a score calculated from several substances in the blood that reflect inflammation and metabolic stress. It captures biological signals that tests based on liver scarring alone may not show. 

Fatty liver disease affects about 1 in 3 adults worldwide, but only some get very sick, progressing to serious complications such as liver failure, liver cancer or death. A key challenge for physicians is identifying which patients are at greatest risk. Currently, risk assessment may include routine laboratory testing to measure the level of scarring, or fibrosis; diagnostic imaging; and, in some cases, liver biopsy. 

A paper published June 23 in Nature Communications by a U.S. research team led by Arun Sanyal, M.D., director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at VCU, showed that higher MVX scores were strongly linked with worse outcomes. Every 10-point increase in MVX resulted in: 

• 2.7 times higher risk of death from any cause. 
• 5.1 times higher risk of death from liver disease. 
• 2.5 times higher risk of severe liver failure events. 

When MVX was used together with a measurement of fibrosis stage, it predicted outcomes such as death, liver failure and liver cancer better than measuring the fibrosis stage alone. 

For patients and physicians, this could mean: 

• Faster screening of blood tests during routine visits. 
• Less need for invasive tests. 
• More precise decisions on patient monitoring or early intervention. 

The researchers analyzed patient blood tests and clinical records and followed 1,613 patients with MVX data over a period of at least 48 weeks to see who developed serious liver complications. They compared MVX results to standard measures like fibrosis stage to test whether the index added useful risk information. 

Fatty liver disease is common, but only some people progress to severe illness. The study results show that MVX could help doctors identify higher-risk patients earlier using a blood test, which is less invasive and easier to perform than imaging or biopsy. That could let clinicians focus their follow-up care on the patients most likely to benefit. 

Sanyal, who is a professor at VCU School of Medicine, noted that looking only at scarring may miss other important signals. Using blood tests that measure metabolism and inflammation could help doctors pinpoint which patients need follow-up sooner. 

The findings are promising but not definitive, according to Sanyal. He said it should not yet replace existing tests, as additional studies are needed to confirm results across more patient groups and to show how using MVX affects patient care and outcomes. 

From international clinical trials to high-quality patient care, discover how VCU’s Stravitz-Sanyal Institute for Liver Disease and Metabolic Health is making an impact in Virginia and beyond.

Stay informed, stay healthy. For the latest health care news from trusted experts, subscribe to VCU Health’s e-mail newsletter